Long-term results for tucatinib added to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (HER2CLIMB study) presented at conference

Data from exploratory analysis found the overall survival (OS) benefit observed at the time of the primary analysis was maintained after 29.6 months of follow-up, with a median OS of 24.7 months vs. 19.2 months for control (HR 0.73; 95% CI 0.59-0.90; p=0.004).

Source:

Biospace Inc.